Condition: Xerostomia in Patients with Radiated Head and Neck Cancer (HNC)
Journal: BMC oral health
Treatment Used: Integrative Supportive Program
Number of Patients: 92
Published: May 23, 2022
Summary: Effects of an integrated supportive program on xerostomia and saliva characteristics in patients with head and neck cancer radiated with a low dose to the major salivary glands: a randomized controlled trial.
Condition: Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Journal: Investigational new drugs
Treatment Used: Tarloxotinib
Number of Patients: 30
Published: April 18, 2022
Summary: A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.